Skip to main content

Benitec Licenses Expressed RNAi Tech to Calimmune

Premium

Benitec Biopharma said this week that it has non-exclusively licensed its expressed RNAi technology to Calimmune for use in developing an RNAi-based HIV/AIDS treatment.

The deal covers the use of Benitec's technology against up to three viral and cellular genes identified as having therapeutic potential against HIV, Benitec said.

Additional terms of the deal were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.